US Deep Vein Thrombosis Treatment Market

ID: MRFR/HC/51017-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026
US Deep Vein Thrombosis Treatment Market Research Report By Drug Class (Anticoagulants, Heparin, Others), By Treatment (Surgery, Drugs, Others), By Mode Of Administration (Injectable, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By End-User (Hospitals, Homecare, Specialty Clinics, Others) -Forecast to 2035
US Deep Vein Thrombosis Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.5%
2024 Market Size$ 206.41 Million
2025 Market Size$ 221.89 Million
2035 Market Size$ 457.41 Million
Key Players
Bayer AG
Bristol-Myers Squibb Company
Johnson & Johnson
Sanofi S.A.
Pfizer Inc.
AstraZeneca PLC
Trends
  • Technological Integration
  • Regulatory Changes
  • Personalized Medicine
Opportunities
  • Rising Incidence of Risk Factors
  • Increased Awareness and Education
  • Advancements in Treatment Modalities
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Drug Class (USD Million)
      1. 4.1.1 Anticoagulants
      2. 4.1.2 Heparin
      3. 4.1.3 Others
    2. 4.2 Industrial Automation & Equipment, BY Treatment (USD Million)
      1. 4.2.1 Surgery
      2. 4.2.2 Drugs
      3. 4.2.3 Others
    3. 4.3 Industrial Automation & Equipment, BY Mode Of Administration (USD Million)
      1. 4.3.1 Injectable
      2. 4.3.2 Oral
      3. 4.3.3 Others
    4. 4.4 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
      1. 4.4.1 Hospital Pharmacies
      2. 4.4.2 Retail Pharmacies
      3. 4.4.3 Online Pharmacies
    5. 4.5 Industrial Automation & Equipment, BY End-User (USD Million)
      1. 4.5.1 Hospitals
      2. 4.5.2 Homecare
      3. 4.5.3 Specialty Clinics
      4. 4.5.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bayer AG (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Johnson & Johnson (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi S.A. (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer Inc. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca PLC (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche Holding AG (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Novartis AG (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 US MARKET ANALYSIS BY TREATMENT
    4. 6.4 US MARKET ANALYSIS BY MODE OF ADMINISTRATION
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 US MARKET ANALYSIS BY END-USER
    7. 6.7 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 (% SHARE)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    20. 6.20 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    21. 6.21 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 (% SHARE)
    22. 6.22 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Deep Vein Thrombosis Treatment Market Segmentation

US Deep Vein Thrombosis Treatment Market By Drug Class (USD Million, 2025-2035)

  • Anticoagulants
  • Heparin
  • Others

US Deep Vein Thrombosis Treatment Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Drugs
  • Others

US Deep Vein Thrombosis Treatment Market By Mode Of Administration (USD Million, 2025-2035)

  • Injectable
  • Oral
  • Others

US Deep Vein Thrombosis Treatment Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

US Deep Vein Thrombosis Treatment Market By End-User (USD Million, 2025-2035)

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.